Par Pharmaceuticals announced the launch of Megestrol Acetate Suspension, the generic version of its brand Megace ES. Megace ES is a progestin indicated for the treatment of anorexia, cachexia, or ...
NEWARK (CN) - Par Pharmaceuticals pleaded guilty and will pay $45 million in criminal and civil fines for promoting its anorexia drug Megace ES for off-label uses, federal prosecutors said. Doctors ...
March 5 (Reuters) - Par Pharmaceutical Cos, a generic drugmaker, has pleaded guilty to improperly marketing a medication intended to address appetite loss in AIDS patients, and agreed to pay $45 ...
Tuesday, March 5, 2013--New Jersey-based Par Pharmaceutical Companies Inc. pleaded guilty in federal court today and agreed to pay $45 million to resolve its criminal and civil liability in the ...
WOODCLIFF LAKE, N.J., Oct. 14, 2011 /PRNewswire via COMTEX/ -- Par Pharmaceutical, Inc., the wholly-owned subsidiary of Par Pharmaceutical Companies, Inc. /quotes ...
(Reuters) - A Maryland judge on Thursday refused to block TWi Pharmaceuticals from marketing a generic version of Megace ES while brand-name manufacturer Par Pharmaceutical challenges a recent ruling ...
LONDON (MarketWatch) -- Par Pharmaceutical Companies said it's won Food and Drug Administration approval for Megace ES, a treatment for anorexia, cachexia or AIDS-related weight loss. Par said Megace ...
July 14, 2005 -- The U.S. Food and Drug Administration (FDA) has approved isosorbide dinitrate/hydralazine HCl tablets for use in self-identified black patients as an adjunct to standard heart failure ...
TWi Pharmaceuticals announced the launch of Megestrol Acetate Suspension, the generic version of Par Pharmaceutical’s Megace ES. Megace ES is a progestin indicated for the treatment of anorexia, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback